Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 17,600,800 | 15,557,700 | 12,728,500 | 13,532,800 | 11,439,100 |
| Cost of Goods | 3,008,300 | 2,447,800 | 2,224,200 | 2,403,800 | 2,170,800 |
| Gross Profit | 14,592,500 | 13,109,900 | 10,504,300 | 11,129,000 | 9,268,300 |
| Operating Expenses | 7,227,300 | 6,243,700 | 6,809,399 | 6,415,996 | 7,742,700 |
| Operating Income | 7,365,500 | 6,867,000 | 3,695,101 | 4,713,803 | 1,526,399 |
| Other Income | -133,100 | -90,600 | -239,001 | 324,897 | 62,001 |
| Pre-tax Income | 7,232,400 | 6,776,400 | 3,456,100 | 5,038,700 | 1,588,400 |
| Income Tax | 1,649,900 | 1,115,900 | 696,800 | 628,900 | 618,100 |
| Net Income Continuous | 5,582,500 | 5,660,500 | 2,759,300 | 4,409,800 | 970,300 |
| Net Income | $5,582,500 | $5,660,500 | $2,759,300 | $4,409,800 | $970,300 |
| EPS Basic Total Ops | 6.22 | 6.30 | 3.07 | 4.90 | 1.08 |
| EPS Basic Continuous Ops | 6.22 | 6.30 | 3.07 | 4.90 | 1.08 |
| EPS Diluted Total Ops | 6.21 | 6.29 | 3.06 | 4.88 | 1.07 |
| EPS Diluted Continuous Ops | 6.21 | 6.29 | 3.06 | 4.88 | 1.07 |
| EPS Diluted Before Non-Recurring Items | 7.02 | 6.31 | 3.34 | 5.32 | 1.18 |
| EBITDA(a) | $7,835,500 | $7,345,500 | $4,157,900 | $5,198,604 | $1,993,199 |